Selected Articles

Ladenstein R, Pötschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, van den Berg H, Dirksen U, Hjorth L, Michon J, Lewis I, Craft A and Jürgens H. (2010 ) Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 Trial. J Clin Oncol. 201:28(21):3284-91. 

Ladenstein R, Valteau-Couanet D, Brock P, Yaniv I, Castel V, Laureys G, Malis J, Papadakis V, Lacerda A, Ruud E, Kogner P, Garami M, Balwierz W, Schroeder H, Beck-Popovic M, Schreier G, Machin D, Pötschger U, Pearson A. (2010) Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study. J Clin Oncol. 28(21):3516-24 

Ladenstein R, Pötschger U, Siabalis D, Garaventa A, Bergeron C, Lewis IJ, Stein J, Kohler J, Shaw PJ, Holter W, Pistoia V, Michon J. (2011) A dose finding study for the effective use of subcutaneous rIL-2 in an outpatient setting for stage 4 neuroblastoma after megatherapy and autologous stem cell reinfusion. J Clin Oncol. 29(4):441-8.

Ladenstein R, Weixler S, Garaventa A, Baykan B, Bleeke M, Kunert R, Katinger D, Pribill I, Glander P, Bauer S , Pistoia V, Michon J, Lode HN (2013) Ch14.18 Antibody Produced in CHO Cells in Relapsed or Refractory Stage 4 Neuroblastoma Patients: A SIOPEN Phase 1 Study. Landesbioscience mAbs. 5(5):801-9

Viprey V, Gregory W, Corrias M, Tchirkov A, Swerts K, Vicha A, Dallorso S, Brock P, Luksch R, Valteau-Couanet D, Papadakis V, Laureys G, Schreier G, Pötschger U, Ladenstein R and Burchill S (2013) The level of neuroblastoma mRNA detected by RTq PCR in blood and bone marrow aspirates preditcs event-free and overall survival in children with stage 4 neuroblastoma: a SIOPEN Molecular Monitoring Group study. NEJM. July 2013

The Clinical Trial Unit for Studies & Statistics for Integrated Research & Projects (S2IRP) is an important link between the CCRI laboratory research activities and the clinical application of trials at the St. Anna Children’s Hospital. Essentially, S2IRP fosters clinical research in paediatric oncology by coordinating and facilitating international clinical trials.

Within the CCRI, the S2IRP is the centre of excellence for clinical studies and statistics. The S2IRP acts as the study centre for prospective clinical trials aiming to optimise therapies according to EU directives and the Austrian Pharmaceuticals Act (AMG). In addition, by running specific projects various international cooperations are maintained. The skilled multidisciplinary team and personnel resources enable the preparation, coordination and quality-control of TOS. This allows verification of the results and implementation of innovative stratifying diagnostics to optimise risk-adapted treatments.

For more information about our Clinical Trial Unit please visit the S2IRP section.

European Network for Cancer Research in Children and Adolescents (ENCCA)
ENCCA was successfully submitted under the European Union’s Seventh Framework Programme health topic “Structuring clinical research in paediatric and adolescent oncology in Europe” in November, 2009. This Network of Excellence aims to restructure knowledge-sharing through the integration of the whole chain of stakeholders from the European paediatric oncology community and will support the acceleration of the development of innovative therapeutic strategies for children and adolescents with cancer. ENCCA will be managed through the CCRI and S²IRP: the Network of Excellence coordinator is Dr. Ruth Ladenstein, also current president of SIOP Europe. 33 European institutions in 16 countries are involved and will deliver 80 milestones including manifold deliverables.

In summary, ENCCA goals include:

  • Structure and integrate, on a sustainable basis and at a pan-European scale, clinical and translational research in children and young people with cancer by proposing a European Strategy for Clinical and Translational Research in paediatric and adolescent oncology.
  • Promote innovative methodology and designs for clinical trials, as well as their implementation and integration to address the specific needs of these rare cancers.
  • Initiate harmonised therapeutic strategies by significantly increasing access to knowledge and technologies on paediatric tumour biology and interactions between tumour and host.
  • Improve substantially the quality-of-life of children and adolescents with cancer, in particular the long-term side-effects of current and future treatments.
  • Propose common ethical definitions of issues and solutions adapted to national and cultural requirements, while monitoring ethical issues in the implementation of the European agenda in clinical research.

This ambitious project is designed to integrate all clinical trial groups and stakeholders in the future and is a stepping stone towards an interactive and sustainable European network that can facilitate trials on a European basis and foster the integration of European research tasks. ENCCA will also have a political agenda on behalf of the European Parliament.

ENCCA goes public
Read more about the media activities conducted for the ENCCA project so far.